ArticleBlood advances2026
Sickle cell visualization in vivo in humans: microvascular occlusion formation and hemorheological indices.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lights, camera, occlusion! watch sickle cells in real time.Blood advances · 2026Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
6 authors.
Funding
Abstract
abstractVaso-occlusion is a signature pathology of sickle cell disease (SCD). However, the lack of in vivo methods to observe individual blood cell dynamics in humans limits our understanding of occlusion formation mechanisms. We present a novel in vivo, noninvasive, label-free, and high-resolution imaging technique to study blood flow and sickled cell behavior in affected individuals. We used oblique back-illumination microscopy (OBM) to capture videos of 91.0 ± 42.3 sublingual capillaries in each of 10 participants with SCD before and after red cell transfusions and compared the measurements to 10 unaffected controls. With direct observation of blood cell activity, we identified microvascular occlusions initiated by red blood cells (RBCs) that adhered to the endothelium and caused mechanical vessel obstruction. Often, the RBCs were sickled. Then, in each observed vessel, we classified blood flow as fast, slow, or no flow and counted adhered RBCs. Compared to controls, patients with SCD before transfusion had fewer fast-flowing vessels (48.7% vs 77.7%; P = 5.8 × 10-4), more no flow vessels (16.1% vs 2.4%; P = .0010), and more adhered RBCs (1.37 vs 0.01 cells per vessel; P = .0025). From before to after transfusion, SCD microvasculature had increased fast-flowing (48.7% vs 65.8%; P = .0098) and decreased no flow vessels (16.1% vs 6.0%; P = .0039); adhered RBCs decreased (1.37 vs 0.71 cells per vessel; P = .043). These hemorheological indices captured transfusion-induced changes to vascular dynamics and events leading to microvascular dysfunction and occlusion in SCD. Our findings demonstrate the potential of OBM to study vaso-occlusion pathobiology, accelerate therapeutic evaluation, and personalize treatment strategies in people with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.